CanSino Biologics, Inc. Class H (HK:6185) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CanSino Biologics Inc. announced that its supplemental drug application to expand the age range for its Menhycia vaccine has been accepted by China’s National Medical Products Administration. This move is expected to enhance the company’s market presence, as it continues to experience strong revenue growth, with a 39.07% increase in sales of meningococcal vaccines in the first three quarters of 2024 compared to the previous year. Investors may find this development promising as CanSino strengthens its competitive edge in the vaccine industry.
For further insights into HK:6185 stock, check out TipRanks’ Stock Analysis page.